natgillin/translations-raw huggingface dataset:
In some embodiments, R2 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl and substituted or unsubstituted heterocyclyl, with the proviso that a carbon atom is attached to the carbonyl. 
Farmaceutski pripravak naznačen time da sadrži terapeutski učinkovitu količinu spoja prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol koji ima strukturu s Formulom I: pri čemu R' je supstituiran ili nesupstituiran heteroaril, pri čemu je heteroaril odabran iz skupine koju čine
A vaccine for use in inhibiting proliferation of cells expressing a gene of SEQ ID NO: 1, wherein the vaccine comprises at least one peptide selected from the group consisting of: 
Cjepivo namijenjeno upotrebi u inhibiranju proliferacije stanice koja eksprimira gen iz SEQ ID NO: 1, naznačeno time što cjepivo sadrži peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 7 kao aktivni sastojak.
welding said shaped layer (8) to seal and cover the bottom surface of said first thermoformed layer (7). 
(XI) - zavarivanje navedenog oblikovanog sloja (8) kako bi se pokrila i zatvorila donja površina navedenog prvog termoformiranog sloja (7).
Method according to claim 1, wherein the mixture comprises an organic solvent in an amount of from 0 to 5 % by weight based on the amount of water. 
Postupak prema zahtjevu 1, naznačen time da smjesa sadrži organsko otapalo u količini od 0 do 5 % težinski temeljeno na količini vode.
reduction of pressure on the articles which are to be sterilized, by means of the liquid ring pump, which is employed prior to action of the mechanical vacuum pump, in order to attain a required pressure of the plasma; 
- < snižavanje tlaka na predmetima koje treba sterilizirati pomoću crpke s tekućim prstenom (5) nakon mehaničke vakuumske crpke (4) kako bi se postigao potrebni tlak plazme;
EPMATHMARKEREP denoting the joint average P, B and b frame sizes per GOP; 
5:9, koji označuje zajednički prosjek veličina P, B i b kadra po GOP-u;
said controller being further configured to periodically update the identifier stored in said identifier memory to identify said one of said storage locations as the one containing the most recent data element, and 
- mjerenje potrošnje komunalnih usluga na način da se identifikator (ID) pohranjen u sredstvu za identifikaciju (IDSM) periodički ažurira kako bi identificirao sljedeću od lokacija za pohranu kao onu koja sadrži posljednji podatkovni element, i
a gradient calculating device configured to calculate magnitude and a direction of gradient of a pixel value for each pixel of the band image; 
uređaj za izračun gradijenta (13) koji ima konfiguraciju za izračunavanje magnitude i smjera gradijenta (m) od vrijednosti piksela za svaki piksel u slici na traci (a, B, Y);
Stability testing was carried during 3 months at a storage temperature of 40°C/70% RH. 
Testiranje stabilnosti izvedeno je u trajanju od 3 mjeseca na temperaturi čuvanja od 402C/70% relativne vlažnosti.
A binder composition according to claim 4 characterized in that the total amount of silane present is from 0.2% to 1.0% by weight based on the weight of the binder composition. 
Vezivna smjesa prema bilo kojem od zahtjeva 4 ili 5 naznačena time da je ukupna količina prisutnog silana od 0.2% do 1.0% težinski temeljeno na težini vezivne smjese.
The compound for use according to embodiment 11, wherein the inflammatory bowel disease is Crohn's disease. 
Spoj za upotrebu prema zahtjevu 18, pri čemu upalna bolest crijeva je Crohnova bolest.
The current specification also discloses a first example of a method for conveying of pre-printed polymer oblates (IML), which are e.g. 
HR P20181927 T1 PATENTNI ZAHTJEVI Postupak transportiranja predotisnutih polimernih spljoštenih objekata (IML), koje se primjerice proizvodi u tzv.
A pharmaceutical composition according to any of [12] to [18] wherein the composition is lyophilised. 
Farmaceutski sastav u skladu s patentnim zahtjevima 10 ili 11 pri čemu je sastav liofiliziran.
A combined preparation according to claim 31 wherein said condition related to diabetes is selected from the group consisting of hyperglycemia, impaired glucose tolerance, insulin resistance, pancreatic beta-cell insufficiency, enteroendocrine cell insufficiency, glucosuria, metabolic acidosis, cataracts, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic coronary artery disease, diabetic cerebrovascular disease, diabetic peripheral vascular disease, metabolic syndrome, hyperlipidemia, atherosclerosis, stroke, hypertension, and obesity. 
Pripravak u skladu sa zahtjevom 35, naznačen time, da služi za liječenje ili prevenciju stanja povezanih s dijabetesom izabranih iz skupine koju čine hiperglikemija, smanjena tolerancija glukoze, inzulinska rezistencija, insuficijencija beta-stanica pankreasa, insuficijencija enteroendokrinih stanica, glikozurija, matabolička acidoza, katarakte, dijabetička nefropatija, dijabetička neuropatija, dijabetička retinopatija, dijabetičko oboljenje srčanih arterija, dijabetička cerebrovaskularna bolest, dijabetička periferna vaskularna bolest, metabolički sindrom, hiperlipidemija, ateroskleroza, udar, hipertenzija i debljina.
The apparatus according to claim 9, further comprising a piston seat spring disposed within the piston seat cavity configured to bias the piston seat cover in a first direction. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time da nadalje sadrži oprugu sjedišta klipa (150) postavljenu unutar šupljine sjedišta klipa (160) konfiguriranu da zakreće poklopac sjedišta klipa (130) u prvom smjeru.
The combined organic extracts were washed with water, saturated aqueous NaHCO3, water, and brine, and then dried and concentrated to give 1.44 g N-a-(tert-butoxycarbonyl)-5-(4-biphenylylmethyl)-L-cysteine (82% yield) as a white solid. 
Kombinirani organski ekstrakti isprani su vodom, zasićenom otopinom NaHCO:, vodom, slanom otopinom, i nakon toga sušeni i koncentrirani uz dobivanje 1.44 g N-a- (terc-butoksikarbonil)-S-(4-bifenilmetil)-1-cisteina (82%) kao bijele krutine.
wherein R1 is hydrogen or C1-6-alkyl, comprising the conversion of a 2-trifluoromethyl pyridine derivative of the formula wherein X is halogen or —OSO2CY3, wherein Y is halogen, by either palladium-catalyzed: (i) cyanation of II and subsequent hydrolysis of the nitrile to afford I, or, (ii) carbonylation of II in the presence of R1OH to afford I. The process of claim 1, wherein the conversion comprises the palladium-catalyzed reaction of II with carbon monoxide (CO) in the presence of the reactant R1OH, wherein R1 is hydrogen or C1-6-alkyl. 
CF, pri čemu R' predstavlja vodik ili C,«-alkil i obuhvaća konverziju 2-trifluorometil piridin derivata prema sljedećoj formuli: X x il £ NC gdje X predstavlja halogen ili -OSO;CY:, dok Y je halogen, s ugljičnim monoksidom (CO); u prisutnosti reaktanta R'OH, pri čemu R' ima značenje koje je gore navedeno i u prisutnosti paladijevog kompleksa koji djeluje kao katalizator odabran iz paladij(ID)klorida s ligandom 1,1'-Bis-(difenilfosfino)ferocen (dfff).
A method for improving the hydrophobic properties of a fiber cement product, said method comprising the steps of: 
Postupak za poboljšanje hidrofobnih svojstva vlaknastog cementnog proizvoda, naznačen time što navedeni postupak sadrži korake
the treatment of tuberculosis; the treatment of latent tuberculosis; the prevention of latent tuberculosis; 
(a) liječenju tuberkuloze; (b) liječenju latentne tuberkuloze; (c) sprječavanju latentne tuberkuloze;
A compound represented by general formula [2]: wherein 
X2 predstavlja skupinu opće formule [3]:
adding at least one monodentate aromatic phosphine and optionally 1,3-butadiene, and continuing said stereospecific polymerization, in order to obtain said stereoregular diblock polybutadiene composed of a polybutadiene block having a 1,4-cis structure and a polybutadiene block having a 1,2 syndiotactic structure. 
dodavanju najmanje jednog monodentatnog aromatskog fosfina i izborno 1,3-butadiena, uz nastavak navedene stereospecifične polimerizacije kako bi se dobilo navedeni stereoregularni diblok polibutadien, koji se sastoji od polibutadienskog bloka, koji ima 1,4-cis strukturu, i polibutadienskog bloka, koji ima 1,2 sindiotaktičku strukturu.
There is therefore a great demand for the development of alternative media free from animal sources that support cell growth and maintain cells during the production of biologically active products. 
Stoga postoji velika potreba razvoja alternativnih medija bez životinjskih izvora koji podržavaju stanični rast i održavanje stanica tijekom proizvodnje biološki aktivnih produkata.
A compound of formula (I): wherein: 
Spoj čija je formula (I): gdje je:
Procedure ml of purified water is used as the granulating solution to prepare granules by mixing with nebivolol hydrochloride adsorbed blend till the mass of required consistency was obtained. 
Postupak 50 ml pročišćene vode je rabljeno kao otopina za granulaciju da bi se dobile granule miješanjem smjese s adsorbiranim nebivolol hidrokloridom dok nije dobivena masa tražene konzistencije.
with the variables as defined in claim 1; converting an intermediate of formula (XIX) in the presence of a strong acid in a suitable solvent to obtain compounds of formula (III) 
OH sa varijablama kako je definirano u zahtjevu I; konverziju intermedijera prema formuli (XIX) u prisutnosti jake kiseline u prikladnom otapalu da se dobiju spojevi formule (III)
After collection, the solution was immediately brought to pH 9.1±0.1 by adding 50 mM solid sodium tetraborate. 
Nakon sakupljanja, otopini je odmah podešen pH 9.1 + 0.1 dodavanjem 50 mM krutog natrijevog tetraborata.
Analytical LC-TOF data were obtained on a 4 channel Micromass LCT instrument equipped with MUX electrospay source and Waters 1525 LC system. 
Analitički LC-TOI' podaci dobiveni su na 4-kanalnom instrumentu Micromass LCT opremljenom MUX elektrosprej izvorom i sustavu Waters 1525 LC.
Pharmaceutical composition according to one of the claims 1 to 5 comprising the antibody or antigen-binding fragment thereof as liquid formulation in a hermetically sealed container selected from the group consisting of a vial, a sachette, a pre-filled syringe, a pre-filled autoinjector, a cartridge for a reusable syringe, and an applicator. 
Farmaceutski pripravak za uporabu u skladu s jednim od patentnih zahtjeva 1 do 11, naznačen time da oblik jediničnog doziranja sadrži protutijelo ili njegov fragment koji veže antigen kao tekuću formulaciju i u hermetički zatvorenoj posudi odabranoj iz skupine koju čine bočica, vrećica, prethodno napunjena štrcaljka, prethodno napunjeni autoinjektor, uložak za višekratnu štrcaljku, i aplikator.
In another embodiment, the isolated antigen binding protein is coupled to an effector group such as, for example, a radioisotope, a radionuclide, a toxin, a therapeutic group, or a chemotherapeutic group. 
Izolirano protutijelo ili fragment protutijela iz bilo kojeg od patentnih zahtjeva 1-4, pri čemu je navedeno protutijelo ili fragment protutijela vezano za efektorsku grupu, pri čemu je navedena efektorska grupa radioizotop, radionuklid, toksin, terapijska grupa ili kemoterapijska grupa.
simultaneously heating and pressing the stack of sheets to fuse points of contact between the nanofibres of adjacent sheets, and 
(II) istovremenog zagrijavanja i prešanja snopa listova radi spajanja kontaktnih točaka između nanovlakana susjednih listova, i
The surfactant can be one of sodium lauryl sulphate, polyoxyethylene polyoxypropylene glycol, polyethylene glycol, poplypropylene glycol, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol, macrogolglycerol hydroxystearate or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 15, naznačena time što se površinski aktivna tvar sastoji od natrijeva lauril-sulfata, polioksietilen polioksipropilen glikola, polietilen glikola, polipropilen glikola, polivinil kaprolaktama-polivinil acetata-polietilen glikola, makrogolglicerol hidroksistearata ili kombinacija navedenog.
the first encoding means encodes the encoding target frame after the coding initialization means. A decoding device including a first decoding means operating under a linear predictive coding scheme and a second decoding means operating under a coding scheme which is different from the linear predictive coding scheme and decoding an encoded audio signal using the first decoding means and the second decoding means, the decoding device comprising: 
Uređaj za dekodiranje (20), koji sadrži prvi dekoder (24), koji radi prema linearnoj prediktivnoj shemi kodiranja, i drugi dekoder (25), koji radi prema shemi kodiranja koja se razlikuje od linearne prediktivne sheme kodiranja, gdje se kodirani audio signal i dekodira uz pomoć prvog dekodera i drugog dekodera, naznačen time što uređaj za dekodiranje (20) sadrži:
the subscript m is 0 or 1; and the subscript p is 0 or 1. 
donji indeks m je 0 ili 1; i donji indeks p je 0 ili 1.
An example of variation of the process parameters (thickness, reduction %, temperature and speed) is shown under the lay-out representation of FIG. 1 in correspondence with various positions at the inlet and outlet of the induction furnace 12, descaler 16 and rolling stands. 
Primjer izmjena parametara postupka (debljina, smanjenje u %, temperatura i brzina) pokazan je ispod postrojenja na Slici 1, u odnosu na različite položaje ulazne i izlazne indukcijske peći 12, čistača 16 1 valjačkih stanova.
A pharmaceutical aerosol solution composition according to claim 4 wherein the stabilising amount of a mineral acid is an amount of acid equivalent to 1M hydrochloric acid in the range from 0.200 to 0.227 µg/µl. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 4 u kojem stabilizirajuća količina mineralne kiseline jest količina kiseline ekvivalentna IM klorovodične kiseline u rasponu od 0,200 do 0,227 ng/ul.
Item 27 A transgenic plant cell or transgenic plant obtained according to the method of item 25 or 26. 
Transgenska biljna stanica ili transgenska biljka, naznačena time, da se dobiva u skladu s postupkom prema zahtjevu 10ili 11.
(m-1) adding water and allowing crystallisation of the compound of the Formula X to occur, collecting the compound of the Formula X and washing the compound of the Formula X with water, followed by a solvent selected from ethyl acetate, butyl acetate and acetonitrile at a temperature in the range of from 25 to 55°C; or 
(m-1) dodavanja vode i dozvoljavanja kristalizacije spoja sa formulom X, i sakupljanja spoja sa formulom X i 15 pranja spoja formule X sa vodom, te nakon toga sa otapalom izabranim između otil acetata, butil acetata i acetonitrila na temperaturi u rasponu od 25 do 55?
with a compound to yield a compound of formula I: wherein X, X1, X2, R1, L and Y are as defined in claim 1. 
Xx2 se / I pri čemu X, x!, x", R', Li Y su kako je definirano u zahtjevu 1.
The filler ingredient and the composite material are preferably as defined herein. 
Sastojak za punjenje i kompozitni materijal preferirano jesu kao što su ovdje definirani.
The extended release tablet formulation of any preceding claim, wherein the water swelling polymer, which is not pregelatinized starch or an anionic polymer, is selected from hydroxypropylcellulose and hydroxypropylmethylcellulose. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 4, naznačena time, da u biti neutralan polimer je izabran između hidroksipropilceluloze i hidroksipropilmetilceluloze.
2,4-diamino-6-bromomethylpteridine 2 was obtained by standard methods (see, for example, U.S. Pat. 
2,4-diamino-6-bromometilpteridin 2 dobiven je standardnim metodama (vidi, na primjer, US 4,077,957 1 US 4,224,446).
Cysteamine for use according to claim 6 or 7 wherein the hepatic aminotransferaseis selected from the group consisting of aspartate aminotransferase and alanine aminotransferase. 
Cisteamin namijenjen upotrebi u skladu s patentnim zahtjevom 6 ili 7, naznačen time što se jetrena aminotransferaza bira iz skupine koju čine aspartatna aminotransferaza i alaninska aminotransferaza.
Examples of cancer to be treated herein include, but are not limited to, B cell proliferative disorder is selected from lymphoma, non-Hogkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma. 
Farmaceutski sastav prema zahtjevu 16 za uporabu prema zahtjevu 17, naznačen time, da je proliferativni poremećaj B-stanice odabran od sljedećih: limfom, non-Hodgkinov limfom (NHL), agresivni NHL, recidivni agresivni NHL, recidivni indolentni NHL, otporan NHL, otporan indolentni NHL, kronična limfocitna leukemija (CLL), mali limfocitni limfom, leukemija, leukemija kosmatih stanica (HCL), akutna limfocitna leukemija (ALI), limfom plaštenih stanica.
In order to ensure optimal growth or an increased protein production, the medium should contain micronutrients for the respective cells, in particular mineral substances. The medium preferably comprises nitrate ions, preferably in a concentration of at least 0.2 mM, phosphate ions, preferably in a concentration of at least 0.05 mM, sulfate ions, preferably in a concentration of at least 0.02 mM, calcium ions, preferably in a concentration of at least 0.1 mM, potassium ions, preferably in a concentration of at least 0.1 mM, or combinations thereof. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što medij sadrži nitratne ione, poželjno u koncentraciji od najmanje 0,2 mM, fosfatne ione, poželjno u koncentraciji od najmanje 0,05 mM, sulfatne ione, poželjno u koncentraciji od najmanje 0,02 mM, kalcijeve ione, poželjno u koncentraciji od najmanje 0,1 _mM, kalijeve ione, poželjno u koncentraciji od najmanje 0,1 mM, natrijeve ione, poželjno u koncentraciji od najmanje 20 mM, ili njihove kombinacije.
evaporating a solvent phase of the aqueous sizing composition and thermal setting a non-volatile residue of the composition. 
- isparavanje otapala vodenastog veziva za ljepljenje i toplinsko vezivanje ne-hlapljivog ostatka smjese.
In particular brassica napus (oilseed rape, canola) seeds coming from fields treated with the herbicidal compositions and synergistic herbicidal mixtures according to the invention usually have higher seed purity. 
Posebno sjeme Brassica napus (uljana repica, kanola) iz polja tretiranih herbicidnim kompozicijama i sinergističkim herbicidnim smjesama prema izumu obično ima veću čistoću sjemena.
The dispenser as claimed in claim 26, further comprising a tolerance adjustment mechanism. 
Dispenzer kao što je navedeno u zahtjevu 32, 33 ili 34, dalje sadržeći mehanizam za prilagodbu tolerancije.
A compound according to claim 1 wherein A is phenyl or 6-membered heteroaryl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je A fenil ili 6-eročlani heteroaril.
The method of claim 21, wherein the bacterial disease, bacterial infection or bacterial colonization is a bacterial disease, a bacterial infection or bacterial colonization of the skin or a mucous membrane, wherein the mucous membrane is of the upper respiratory tract, or of the nasal cavity. 
Kimerni polipeptid ili pripravak, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 10 do 13, naznačeni time što je bakterijska bolest, bakterijska infekcija ili koloniziranje bakterija bakterijska bolest, bakterijska infekcija ili koloniziranje bakterija na koži ili sluznici, po mogućnosti sluznici gornjeg dišnog sustava, poželjnije sluznici nosne šupljine. no
A pharmaceutical composition comprising a compound according to any one of the preceding claims or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient, wherein the pharmaceutical composition optionally comprises a further active ingredient selected from the group consisting of a) an antagonist of integrin a5B1, b) a cytotoxic/antiproliferative agent, c) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factor, d) an inhibitor of VEGF, e) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tic-1, and f) an inhibitor of phosphoinositide 3-kinase, and a mixture thereof. 
S SA ili njegova farmaceutski prihvatljiva sol ili solvat. Farmaceutski preparat, koji sadrži spoj prema bilo kojem od prethodnih patentnih zahtjeva ili njegovu farmaceutski prihvatljivu sol ili solvat, i farmaceutski prihvatljiv nosač ili ekscipijens, naznačen time, da farmaceutski preparat opcijski dalje sadrži aktivni sastojak odabran iz skupine koja se sastoji od a) antagonista integrina o5B1, b) citotoksičnog
The peptide-derived molecule according to claim 10 or the pharmaceutical composition according to claim 10 for use against (i) breast or prostate cancer and/or (ii) other cancers expressing androgen receptors alone or together with estradiol receptors. 
Molekula izvedena iz peptida prema zahtjevu 10 ili farmaceutski pripravak prema zahtjevu 10 naznačen time da je za upotrebu protiv (i) raka dojke ili prostate i/ili (1) drugih karcinoma koji eksprimiraju receptore za androgen zasebno ili zajedno s receptorima za estradiol.
The method according to claim 6 or 7, wherein the neuraminidase inhibitor is oseltamivir or zanamivir. 
Derivat pirazina u skladu sa zahtjevom 6 ili 7, naznačen time, da je neuraminidaza inhibitor oseltamivir ili zanamivir.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule for the use according to claim 17, wherein the disease is multiple myeloma. 
Antitijelo, imunokonjugat, bispecifična ili multispecifična molekula, farmaceutski pripravak ili vektor ekspresije za primjenu prema zahtjevu 19, naznačen time, što je bolest ili poremećaj multipli mijelom.
coenzyme Q10 at a concentration of 0.2 to 1.5% w/v with respect to the final composition, 
koenzim Q10, u koncentraciji od 0,3 do 1,0% tež./vol. u odnosu na gotovi pripravak,
or by the formula (IIIb) 
(lila) ili formulu (IIIb)
Systems and methods for obtaining liquid comestibles from capsules are for example known from EP-A-512470 (counterpart of US 5,402,707), the teaching of which will be explained in the following. 
Poznati su sustavi i postupci za dobivanje tekućih prehrambenih proizvoda iz čahura, na primjer, iz EP-A-512470 (prijepis US 5,402,707), a saznanja iz ove publikacije će biti objašnjen u tekstu koji slijedi.
The liquid formulation according to claim 1, wherein said salt is the D-Lactic acid addition salt. 
Tekuća formulacija u skladu s patentnim zahtjevom 1, pri čemu je navedena sol dodatna sol D-mliječne kiseline.
Enzyme-composition according to any of the foregoing claims, wherein the enzyme-composition additionally contains at least one hemicellulase selected from the group of xylanases, xylosidases, esterases, arabinofuranosidases, galactanases, peroxidases and oxidases. 
Spoj enzima prema jednom od prethodnih patentnih zahtjeva naznačen time da spoj enzima sadrži bar jednu hemicelulazu izabranu iz grupe ksilanaza, ksilozidaza, esteraza, arabinofuranozidaza, galaktanaza, peroksidaza i oksidaza.
Compounds of formula (I) according to claim 1 which are selected from the following list: 
Spojevi s formulom (1) prema zahtjevu 1 koji su odabrani sa sljedećeg popisa:
dC or dT, for use according to claim 1 or 2 respectively, wherein the method of treating further comprises monitoring the subject for an adverse effect after the administration of the composition, wherein if an adverse effect is observed, the therapeutically effective amount of the composition is decreased. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što postupak liječenja dodatno uključuje praćenje subjekta na štetni učinak nakon primjene pripravka, gdje ako se opazi štetni učinak, terapijski djelotvornu količinu pripravka se smanji.
Y is a bond or a linear or branched alkylene group comprising 1 to 8 carbon atoms, which optionally has a cycloalkylidene structure on one carbon atom; and 
Y predstavlja vezu ili ravnu ili razgrananu alkilensku skupinu koja ima 1 do 8 ugljikovih atoma koji po izboru imaju cikloalkilidensku građu na jednom ugljikovom atomu; 1